MVision AI

MVision AI Yhteystiedot, kartta ja reittiohjeet, yhteydenottolomake, aukioloajat, palvelut, arvostelut, kuvat, videot ja ilmoitukset MVision AI, Terveys, PaciuksenKatu 29, Helsinki :ltä.

MVision develops AI-powered solutions that automate repetitive tasks, enable efficient radiotherapy workflows, and promote consistency across clinical processes.

MVision AI will attend the 2026 AAMD Annual Meeting, taking place June 7–10 in Orlando, Florida.The meeting brings toget...
04/06/2026

MVision AI will attend the 2026 AAMD Annual Meeting, taking place June 7–10 in Orlando, Florida.

The meeting brings together medical dosimetrists and radiation oncology professionals for educational sessions, workshops, and discussions focused on current developments in treatment planning and clinical practice.

Martin Clay, VP of Sales US, will be at Booth #102 during the exhibition.

Stop by to say hello and learn more about our AI-powered solutions for radiotherapy planning preparation.

As radiotherapy departments face growing patient volumes and increasing pressure on clinical resources, many teams are e...
02/06/2026

As radiotherapy departments face growing patient volumes and increasing pressure on clinical resources, many teams are exploring where AI can make a meaningful difference.

In this edition of 'Expert Perspectives: AI in Radiotherapy', Christoph Dumke, Dr. med., from Vivantes Berlin-Spandau shares his perspective on how AI-supported contouring is already helping improve workflow efficiency, reduce variability, and support more standardised treatment preparation.

He also reflects on the future of AI-driven planning and personalised radiotherapy workflows.

Read the full interview: https://bit.ly/4flO2yc

Imaging has always been at the core of radiotherapy. What is evolving is the role it plays in planning, adaptation, and ...
28/05/2026

Imaging has always been at the core of radiotherapy. What is evolving is the role it plays in planning, adaptation, and daily decision-making.

Synthetic CT is becoming an important component of these evolving workflows. It supports MR-only planning by removing the need for CT simulation, enables reliable dose calculation from CBCT for adaptive workflows, and helps address the dosimetric impact of contrast when enhanced scans are clinically necessary.

These capabilities are increasingly relevant as departments look to maintain precision while managing growing clinical complexity.

Our latest article explores the clinical evidence behind synthetic CT across MR-only, adaptive, and contrast-enhanced workflows, and what these developments mean for patient care.

You can read the full article here: https://bit.ly/3PNPONV

Every 9 seconds, someone in the EU is diagnosed with cancer.During the European Week Against Cancer, we recognize the im...
25/05/2026

Every 9 seconds, someone in the EU is diagnosed with cancer.

During the European Week Against Cancer, we recognize the importance of prevention, research, early detection, and equal access to care for patients across Europe.

At MVision AI, we believe technology can help healthcare teams work more efficiently and consistently in radiotherapy planning. Our AI-powered solutions are designed to reduce repetitive manual work and support clinicians in delivering high-quality care with confidence.

We’re proud to contribute to a future where innovation helps improve cancer care pathways for both clinicians and patients.

19/05/2026

has come to a close.

Over the past few days in Stockholm, we had the opportunity to connect with customers, clinicians, physicists, researchers, and partners from across the field — all working toward the same goal: improving patient care through smarter, more efficient technology.

The discussions around AI-driven workflows, Workspace+, and the future of radiotherapy were truly inspiring. The insights and feedback shared throughout the congress will help shape our product development as we continue working hard to bring new features and innovations to our customers.

We’re excited for what’s ahead.

See you nest year in Milan.



*CE-marked (CE 2797) medical device under EU MDR 2017/745; Workspace+ is not available in all markets.

Day 3 at , and the conversations keep flowing. We're excited about all the buzz around MVision Workspace® and Image+.It...
17/05/2026

Day 3 at , and the conversations keep flowing. We're excited about all the buzz around MVision Workspace® and Image+.

It’s been great welcoming visitors to Booth C14:31, sharing ideas, and demonstrating what we’ve been working on.

Thank you to everyone who has stopped by so far.

If you haven’t had the chance yet, come visit us or schedule a demo here:
https://bit.ly/43e8SIk



*CE-marked (CE 2797) medical device under EU MDR 2017/745; Workspace+ not available in all markets.

16/05/2026

The first full day of ESTRO 2026 is about to start, and the team is ready for another exciting day in Stockholm.

We're here through Monday showcasing MVision Workspace®+ and Image+ and talking about the future of AI in radiation oncology.



*CE-marked (CE 2797) medical device under EU MDR 2017/745; Workspace+ not available in all markets.

A great afternoon in Stockholm with our distributor network ahead of .Today’s training session was a valuable opportuni...
15/05/2026

A great afternoon in Stockholm with our distributor network ahead of .

Today’s training session was a valuable opportunity to share updates, discuss new developments around MVision Workspace+®, and align on how we continue bringing AI-driven innovation to radiation oncology together.

Thanks to all of our distributors for your partnership, collaboration, and continued commitment to advancing patient care alongside us.

ESTRO 2026 kicks off soon — and the MVision AI team is excited for the days ahead.



*CE-marked (CE 2797) medical device under EU MDR 2017/745; Workspace+ not available in all markets.

In radiotherapy clinical trials, small inconsistencies in contouring can turn into major challenges for data quality, re...
14/05/2026

In radiotherapy clinical trials, small inconsistencies in contouring can turn into major challenges for data quality, review timelines, and study reproducibility.

That’s why MVision AI and AQUILAB by Coexya combined their expertise to bring AI-assisted contour review into RT QA workflows for multicenter trials.

With MVision Contour+® integrated into the ONCO PLACE platform, reviewers can quickly identify:
▸ laterality errors
▸ missing structures
▸ morphological discrepancies

Instead of spending valuable time on routine checks, clinical teams can focus on the cases and decisions that require expert attention.

The impact goes beyond prospective QA workflows. Retrospective re-segmentation of historical datasets can now be performed at scale, enabling new radiomics, dosimetric, and ancillary research opportunities from existing trial data.

Read the joint white paper exploring the workflow and showcasing 3 real-world clinical research use cases from the collaboration:
https://bit.ly/3R9wHyj

07/05/2026

Interested in what MVision AI will be showcasing at ESTRO?

Watch this quick preview from our Founder and CEO, Mahmudul Hasan.



*CE-marked (CE 2797) medical device under EU MDR 2017/745; Workspace+ is not available in all markets.

Osoite

PaciuksenKatu 29
Helsinki
00270

Nettisivu

Hälytykset

Tiedä ensimmäisenä ja anna meille oikeus lähettää sinulle sähköpostitse uutisia ja promootioita MVision AI :ltä. Sähköpostiosoitettasi ei käytetä muihin tarkoituksiin, ja voit perua milloin tahansa.

Oikopolut

Jaa

Kategoria